MYH11

MYH11 (Myosin Heavy Chain 11) is a gene that encodes for a protein known as myosin heavy chain, smooth muscle isoform, which is a critical component of the contractile apparatus in smooth muscle cells. This protein is involved in various cellular processes, including muscle contraction, cell motility, and maintenance of cell shape. Mutations in the MYH11 gene have been associated with several medical conditions, highlighting its importance in human health.

Function

The MYH11 gene product is a type of motor protein that converts chemical energy in the form of ATP into mechanical energy, thus generating force and movement. Specifically, in smooth muscle cells, this protein plays a pivotal role in the contraction process that is essential for various bodily functions such as blood pressure regulation, gastrointestinal movement, and respiratory airway resistance. The MYH11 protein is a component of the thick filaments of the smooth muscle sarcomere, where it interacts with actin, another protein, to facilitate muscle contraction through a cyclic process of attachment, power stroke, detachment, and reattachment.

Genetic and Clinical Significance

Mutations in the MYH11 gene can lead to several disorders, including Aortic Aneurysm, Familial Thoracic 4 (AAT4), a condition characterized by the dilation and eventual rupture of the thoracic aorta. This can result in life-threatening complications such as aortic dissection. The relationship between MYH11 mutations and aortic aneurysms underscores the gene's role in vascular smooth muscle cell function and structural integrity of the aortic wall.

Furthermore, MYH11 mutations have been implicated in Patent Ductus Arteriosus (PDA), a congenital heart defect that results in abnormal blood flow between the aorta and the pulmonary artery due to the failure of the ductus arteriosus to close after birth. This condition can lead to significant cardiovascular complications if not treated.

In addition to these conditions, MYH11 is also a gene of interest in cancer research. Chromosomal translocations involving the MYH11 gene have been identified in certain types of leukemia, such as acute myeloid leukemia (AML). These translocations result in fusion genes that may contribute to the development and progression of cancer by altering cell growth and division.

Research and Therapeutic Implications

Understanding the function of MYH11 and the impact of its mutations offers potential therapeutic targets for treating related disorders. For example, drugs that can modulate the activity of the MYH11 protein might be beneficial in managing conditions like aortic aneurysms by stabilizing the aortic wall and preventing its dilation. Similarly, targeting the pathways affected by MYH11 fusion proteins in leukemia could provide new avenues for cancer treatment.

See Also

• Smooth Muscle
• Aortic Aneurysm
• Patent Ductus Arteriosus
• Acute Myeloid Leukemia

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian